文献速递乳腺MR

新辅助治疗期间乳腺MRI新发可疑病灶的频率与结局

Frequency and Outcomes of New Suspicious Lesions on Breast MRI in the Setting of Neoadjuvant Therapy.
PubMed 文献 · AJR Am J Roentgenol · 2021-01-13

该回顾性数据库研究纳入2010至2018年间用于评估新辅助治疗反应的乳腺MRI检查,最终23例(5.5%)出现新发BI-RADS 4类可疑病灶,无1例为恶性。作者认为新辅助治疗期间新发病灶极不可能代表新发恶性肿瘤,尤其当原发灶显示治疗反应时,但需更大样本研究确认是否可安全避免活检。

要点

  • 新辅助治疗期间乳腺MRI新发可疑病灶发生率5.5%,均为BI-RADS 4类,最终无一例恶性。
  • 新发病灶中56.5%位于对侧、39.1%位于同侧、4.3%累及双侧。
  • 作者认为新辅助治疗期间新发病灶极不可能为恶性肿瘤,尤其原发灶有治疗反应时。

关键影像表现/征象

  • 23个新发可疑病灶中,13个(56.5%)位于已知恶性肿瘤对侧,9个(39.1%)位于同侧,1个(4.3%)累及双侧乳腺。
  • 病灶类型包括肿块16个(69.6%)、非肿块强化5个(21.7%)和焦点2个(8.7%)。
  • 所有新发可疑病灶均评估为BI-RADS 4类,无一例为恶性。

临床应用与阅片要点

  • 作者认为新辅助治疗期间出现的新发病灶极不可能代表新发恶性肿瘤部位,尤其当原发恶性肿瘤显示治疗反应时。
  • 作者提出需更大样本研究确认此情形下是否可安全避免活检。

局限性

  • 原文指出需更大样本研究确认此情形下是否可安全避免活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The purpose of this article was to determine the frequency and outcomes of new suspicious findings on breast MRI after initiation of neoadjuvant therapy. MATERIALS AND METHODS. A retrospective database review identified all breast MRI examinations performed to assess response to neoadjuvant therapy between 2010 and 2018. Cases with new suspicious lesions assessed as BI-RADS 4 or 5 and found after the initiation of neoadjuvant treatment were included. Cases with no pretreatment MRI, cases in which the suspicious lesion was present on the baseline MRI but remained suspicious, and cases with insufficient follow-up were excluded. Radiologic, pathologic, and surgical reports were reviewed. Malignant outcomes were determined by pathologic examination. Benignity was established by pathologic examination, follow-up imaging, or both. A total of 419 breast MRI examinations in 297 women were performed to assess response to neoadjuvant therapy. After exclusions, 23 MRI examinations (5.5%) with new suspicious findings, all assessed as BI-RADS 4, comprised the final cohort. RESULTS. Of the 23 lesions, 13 new suspicious findings (56.5%) were contralateral to the known malignancy, nine (39.1%) were ipsilateral, and one (4.3%) involved the bilateral breasts. Lesion types included mass (16, 69.6%), nonmass enhancement (5, 21.7%) and focus (2, 8.7%). None of the new suspicious findings were malignant. CONCLUSION. New suspicious findings occurred in 5.5% of breast MRI examinations performed to monitor response to neoadjuvant therapy, and none of these new lesions were malignant. Our findings suggest that new lesions that arise in the setting of neoadjuvant therapy are highly unlikely to represent a new site of malignancy, particularly if the index malignancy shows treatment response. Larger studies are needed to confirm whether biopsy may be safely averted in this scenario.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Eckstein DA, Price ER, Hayward JH, et al. Frequency and Outcomes of New Suspicious Lesions on Breast MRI in the Setting of Neoadjuvant Therapy. AJR Am J Roentgenol. 2021. PMID: 33439044. doi:10.2214/AJR.20.22979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。